Navigation Links
GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update

ATLANTA, Aug. 14 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company (the "Company"), today announced its financial results and provided an operational update for the quarter ended June 30, 2007.

Operating Results for the Quarter Ended June 30, 2007

The Company recorded a net loss of $1,333,126 for the three months ended June 30, 2007, compared to net income of $197,750 for the same period in 2006. For the six months ended June 30, 2007, the Company's net loss was $1,920,407 as compared to a loss of $143,456 in 2006. The increase in the net loss during 2007 is attributable to (a) no grant revenues recorded during 2007 as the Company progressed beyond basic research and into product development activities, (b) higher research and development expenses as the Company continued to support its four ongoing Phase I human clinical trials and prepares for initiation of Phase II studies, and (c) overall higher general and administrative expenses primarily due to the additional costs associated with being a public company subsequent to the merger between Dauphin Technology, Inc. and GeoVax, Inc. in September 2006. As of June 30, 2007, the Company reported cash balances totaling $1,009,302.

See the summarized financial information attached. Further information concerning the Company's financial position and results of operations are included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.

Recent Operational Highlights:

* In July, GeoVax announced an early start of two new HIV/AIDS vaccine

clinical (human) trials. These FDA compliant trials were previously

scheduled to start later in 2007 and are the 3rd and 4th in a four

clinical trial series intended to evaluate both human safety and immune

responses to GeoVax's HIV/AIDS vaccines. Starting April 2006, the 1st

of these four trials evaluated a low dose (1/10th of the vaccine dose)

vaccination program. Preliminary results from this blinded trial

demonstrated excellent vaccine safety and positive anti-HIV-1 immune

responses to the vaccine in 9 of 11 participants where 9 people

received GeoVax HIV/AIDS vaccines and 2 received placebos. All trial

participants were normal, healthy individuals. Final results will be

compiled for later public release. The 2nd of four trials, initiated

September 2006, is designed to evaluate results from full dose a

administration of GeoVax HIV/AIDS vaccines. Recent data indicates

excellent safety in this full dose trial with immune response data soon

to be available.

* In June and July, GeoVax announced it engaged Althea Technologies,

Inc., and BioReliance Corporation, as contract manufacturers for its

HIV-1 DNA and HIV-1 MVA (AIDS) vaccines. These vaccines will be

utilized in GeoVax's advanced Phase 2 clinical trials planned for early

2008. GeoVax HIV/AIDS vaccines are designed to prevent development of

Acquired Immunodeficiency Disease (AIDS) caused by the virus known as

HIV-1 by vaccinating individuals prior to AIDS virus infection. The

vaccine regimen employs a two-vaccine "prime-boost strategy." Trial

participants will be administered GeoVax HIV-1 DNA vaccine which

"primes" the immune system followed by GeoVax's HIV-1 MVA (Modified

Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus

components but can not cause AIDS. Safety and immunological results

from earlier as well as ongoing human trials are very encouraging thus

supporting planned acceleration of large scale Phase 2 clinical


* In April, GeoVax announced an extension of a research license signed

4/2005 with Vivalis (Nantes, France) to evaluate Vivalis' EBx(R) cell

lines (avian embryonic derived stem cell lines) for the production of

GeoVax's MVA (Modified Vaccinia Ankara) based HIV/AIDS vaccines.

Results obtained from Vivalis and GeoVax demonstrated that EBx(R) cell

technology is possibly a more economical alternative to chicken

embryonic fibroblasts (CEFs) for the replication of GeoVax specific

recombinant MVA based AIDS vaccines. Simultaneously, GeoVax's promising

results in preclinical trials as well as encouraging and positive

immune response data from two ongoing human trials provided the impetus

for accelerating clinical evaluations of GeoVax's vaccines and for

considering the EBx(R) cell platform in industrial vaccine production.

Vivalis and GeoVax collaborations focus on scaling-up MVA based

HIV/AIDS vaccine production processes in EBx(R) cells. In addition,

Vivalis plans preparation of an EBx(R) platform Biological Master File

for filing with the FDA. In parallel, GeoVax is evaluating plans for an

immunogenicity comparability study of GeoVax's MVA based HIV/AIDS

vaccines produced in CEFs and those produced in EBx(R) cells. This

information may be presented in a pre-IND meeting with the FDA

concerning potential use of this cell line.

Management Commentary

Donald Hildebrand, Chief Executive Officer of GeoVax, commented, "Recent developments at GeoVax encourage and excite us as we continue working toward our ultimate goal of making available a safe and effective vaccine for the prevention of AIDS. We are particularly encouraged by the recent accelerated start date of our two new human clinical trials, resulting primarily from the excellent safety and anti-HIV immune response results obtained to date from our ongoing 1/10th and full dose vaccine trials. We are also pleased with the positive response to our progress at GeoVax as reflected by our recent financing announcement. This substantial $7.5 million investment will enhance our HIV/AIDS vaccine development and human clinical trials program, thus allowing us to push forward into large scale Phase 2 AIDS vaccine trials involving many more human participants."


Condensed Consolidated Statements of Operations

(amounts in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30,

2007 2006 2007 2006


Grant Revenue $ - $479 $ - $479

Operating expenses:

Research and development 701 108 913 336

General and administrative 650 179 1,050 302

1,351 287 1,963 638

Other income (expense)

Interest income 18 6 43 16

18 6 43 16

Net loss $(1,333) $198 $(1,920) $(143)

Income (loss) per common share $(0.00) $0.00 $(0.00) $(0.00)


Balance Sheet Highlights

(amounts in thousands)

June 30, Dec. 31,

2007 2006


Cash and cash equivalents $1,009 $2,088

Other current assets 77 38

Total current assets 1,086 2,126

Property and other assets 242 270

Total assets $1,328 $2,396

Liabilities and stockholders' equity

Current liabilities $515 $193

Stockholders' equity (deficit) 813 2,203

Total liabilities and stockholders' equity $1,328 $2,396

Shares Outstanding 712,835 711,168

About GeoVax Labs, Inc.

GeoVax Inc. is an Atlanta, Georgia USA biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 issued and filed patent applications.

GeoVax's DNA and Recombinant MVA HIV/AIDS vaccines:

* Protected 22 of 23 (96%) non-human primates for over 31/2 years post-

infection with an AIDS causing virus - 5 of 6 non-vaccinates controls

died of AIDS

* Are manufactured and tested under GMP/GLP - EMEA (EU) and FDA guidelines

* Satisfactorily completed early Phase 1 human clinical trial for DNA

HIV/AIDS vaccine

* Are currently in 2 ongoing human trials started in 2006 with positive

immune responses reported in the majority of vaccine recipients as well

as good vaccine safety

* Began 2 additional human trials in June 2007 with a large Phase 2 trial

in planning for 2008

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether; GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Companies Securities and Exchange Commission filings and reports.

SOURCE GeoVax Labs, Inc.

Copyright©2007 PR Newswire.

Related biology technology :

1. Use of the PROTEAN Plus Dodeca Cell for Second-Dimension SDS-PAGE, Rev A
2. In Vitro Measurement of the Second Messenger cAMP: RIA vs. FlashPlate
3. CIOs looking to hire more IT workers in second quarter
4. DNASTAR catches second wave of sequencing
5. 9 tips for making 90 seconds count in an investment pitch
6. City of Hope adds second TomoTherapy system
7. UW-Madison hybrid-vehicle team places second nationally
8. Just one nanosecond: Clocking events at the nanoscale
9. MATCs new computer security program gears up for second semester
10. Weather Central launches second satellite
11. nPoint Secures Second Round of Funding
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... addition of the "2016 Europe Cell ... Innovative Technologies, Competitive Strategies, Opportunities for Suppliers--France, ... their offering. --> ) ... "2016 Europe Cell Surface Markers: Country Volume ...
(Date:12/1/2015)... , Dec. 1, 2015  Symic, a clinical-stage biotherapeutics ... extracellular matrix (ECM), today announced that it has secured ... the company,s pipeline, including its lead candidates SB-030 and ... includes the participation by all existing major investors, as ... the total capital raised by Symic to over $43 ...
(Date:12/1/2015)... December 1, 2015 ... the  "2016 U.K. Virology and Bacteriology Testing ... 100 Tests, Supplier Shares by Test, Innovative ... their offering.  --> ) ... U.K. Virology and Bacteriology Testing Market: Sales ...
(Date:11/30/2015)... CHICAGO , Dec. 1, 2015  An interventional radiology ... according to the preliminary results of a study being presented ... North America (RSNA). ... been done for decades by interventional radiologists as a way ... performing the procedure as a means of treating obesity is ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
Breaking Biology News(10 mins):